Bispecific CS1-BCMA CAR-T Cells Are Clinically Active in Relapsed or Refractory Multiple Myeloma: An Updated Clinical Study

被引：7
|
作者：
Li, Chenggong [1 ]
Wang, Xindi [1 ]
Wu, Zhuolin [1 ]
Luo, Wenjing [1 ]
Zhang, Yinqiang [1 ]
Kang, Yun [1 ]
Xu, Jia [1 ]
Huang, Zhongpei [1 ]
Du, Mengyi [1 ]
Tang, Lu [1 ]
Wu, Jianghua [1 ]
Liao, Danying [1 ]
Kou, Haiming [1 ]
Lu, Cong [1 ]
Jiang, Huiwen [1 ]
Wei, Qiuzhe [1 ]
Ke, Sha [1 ]
Zheng, Jing'e [1 ]
Xiong, Wei [2 ]
Deng, Jun [1 ]
Hu, Yu [1 ]
Mei, Heng [1 ]
机构：
[1] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Inst Hematol, Wuhan, Peoples R China
[2] Wuhan Sian Med Technol Co Ltd, Wuhan, Peoples R China
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-170686
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4573 / 4574
页数：2
相关论文
共 50 条
  • [31] BCMA CAR-T Therapy Is Safe and Effective for Refractory/Relapsed Multiple Myeloma With Central Nervous System Involvement
    Wang, Yiyun
    Zu, Cheng
    Teng, Xinyi
    Yang, Li
    Zhang, Mingming
    Hong, Ruimin
    Zhao, Houli
    Cui, Jiazhen
    Xu, Huijun
    Hongsheng, Alex Chang
    Hu, Yongxian
    Huang, He
    JOURNAL OF IMMUNOTHERAPY, 2022, 45 (01) : 25 - 34
  • [32] Cardiovascular adverse events and outcomes after anti-BCMA CAR-T for relapsed and refractory multiple myeloma
    Stefanie Palfi
    Lauren C. Peres
    Himara Koelmeyer
    Melissa Alsina
    Rachid C. Baz
    Brandon J. Blue
    Salvatore Corallo
    Gabriel De Avila
    Ciara Freeman
    Rebecca Gonzalez
    Ariel Grajales-Cruz
    Kristy Harvey
    Hien D. Liu
    Taiga Nishihori
    Guilherme H. Oliveira
    Laura B. Oswald
    Omar Castaneda Puglianini
    Sruthi Selvakumar
    Alexis Behne Sharma
    Elicia Wang
    Kenneth H. Shain
    Michael Jain
    Frederick L. Locke
    Mohammed Alomar
    Doris K. Hansen
    Dae Hyun Lee
    Blood Cancer Journal, 15 (1)
  • [33] Remission observed from a phase 1 clinical study of CAR-T therapy with safety switch targeting BCMA for patients with relapsed/refractory multiple myeloma.
    Liu, Yarong
    Chen, Zhi
    Wei, Runhong
    Shi, Lin
    He, Feng
    Shi, Zixiao
    Jin, Tao
    Xie, Ronglin
    Wei, Baofeng
    Chen, Jing
    Fang, Hongliang
    Zhu, Bo
    Li, Qi-Jing
    Wang, Pin
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [34] Phase II Study of Fully Human BCMA-Targeting CAR-T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/ Refractory Multiple Myeloma
    Chen, Wenming
    Fu, Chengcheng
    Fang, Baijun
    Liang, Aibin
    Xia, Zhongjun
    He, Yanjuan
    Lu, Jin
    Liu, Hui
    Hou, Ming
    Cai, Zhen
    Yang, Wei
    Hao, Siguo
    Jiang, Songfu
    Jing, Hongmei
    Liu, Jing
    Du, Xin
    Fu, Rong
    Mei, Heng
    Zhu, Zunmin
    Yang, Yanli
    Liu, Hong
    Yuan, Daijing
    Zhao, Hongxia
    Xiao, Jun
    Wang, Wei
    Wang, Huamao
    Li, Zonghai
    BLOOD, 2022, 140 : 4564 - 4565
  • [35] CAR-T cells for the treatment of relapsed/refractory multiple myeloma in 2022: efficacy and toxicity
    Krejci, Martin
    Adam, Zdenek
    Krejci, Marta
    Pour, Ludek
    Sandecka, Viera
    Stork, Martin
    NEOPLASMA, 2022, 69 (05) : 1008 - 1018
  • [36] GPRC5D-targeted CAR-T cell therapy in patients with relapsed or refractory multiple myeloma progressing after or refractory to BCMA CAR-T cell therapy: updated eesults from a phase 2 clinical trial
    Xia, Jieyun
    Li, Zhenyu
    Li, Hujun
    Yan, Zhiling
    Xu, Mengdi
    Xu, Kailin
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S5 - S6
  • [37] The Investigation of Antitumor Effect of Humanized Bispecific BCMA/CD38 CAR-T Cells on Multiple Myeloma
    Chen, Zhaoqi
    Lu, Yang
    Xu, Yingxi
    Qiu, Shaowei
    Gu, Runxia
    Xing, Haiyan
    Tang, Kejing
    Tian, Zheng
    Rao, Qing
    Xiong, Dongsheng
    Wang, Min
    Wang, Jianxiang
    BLOOD, 2022, 140 : 7402 - 7403
  • [38] Clinical Outcomes and Salvage Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Progression on BCMA-Targeted CAR-T Therapy
    Reyes, Kevin R.
    Liu, Yen-Chun
    Huang, Chiung-Yu
    Banerjee, Rahul
    Martin, Thomas
    Shah, Nina
    Wong, Sandy W.
    Wolf, Jeffrey L.
    Arora, Shagun
    Chung, Alfred
    BLOOD, 2022, 140
  • [39] Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
    Christopher T. Su
    J. Christine Ye
    Journal of Hematology & Oncology, 14
  • [40] Prognostic Impact of Clinical Factors and Cell Composition of Apheresis Samples on BCMA CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma
    Marumo, Yoshiaki
    Ri, Masaki
    Ebina, Toru
    Nakamura, Tomoyuki
    Sasaki, Hirokazu
    Kinoshita, Shiori
    Narita, Tomoko
    Suzuki, Tomotaka
    Sanda, Takaomi
    Nanri, Takanori
    Komatsu, Hirokazu
    Iida, Shinsuke
    BLOOD, 2024, 144 : 24116 - 24117
12345